[1] World Health Organization. Global tuberculosis report 2022[R]. Geneva: WHO Press, 2022. https://www. who.int/ tb/publications/global_ report/en/.
[2] 刘剑君,王黎霞.现代结核病学[M]. 2版.北京:人民卫生出版社,2022:849-899.
[3] 王晓君,李月华,易凤莲,等. 1990-2017年中国结核病流行与控制情况[J]. 中华流行病学杂志,2020,41(6):856-860. DOI:10.3760/cma.j.cn112338-20190809-00587.
[4] Long Q, Guo L, Jiang W, et al. Ending tuberculosis in China: health system challenges [J]. Lancet Public Health, 2021, 6(12): e948-e953. DOI: 10.1016/S2468-2667(21)00203-6.
[5] 刘志辉. 在终结结核病的艰难征程中当人人有为[J]. 实用医学杂志,2022,38(6):655-659. DOI:10.3969/j.issn. 1006-5725.2022.06.001.
[6] 郭俊涛. 肺结核患者发现情况评价方法的研究进展[J]. 结核病与肺部健康杂志,2017,6(3):289-293. DOI:10.3969/j.issn.2095-3755.2017.03.022.
[7] 胡远莲,艾萍,贾雪娇,等. 2011—2021年北京市丰台区肺结核流行特征分析[J]. 中华预防医学杂志,2022,56(9):1302-1306. DOI:10.3760/cma.j.cn112150-20220408- 00338.
[8] 陆唤,黄诚. 2011-2015年上海市崇明区肺结核疫情分析[J]. 中国防痨杂志,2018,40(5):548-552. DOI:10.3969/j.issn.1000-6621.2018.05.020.
[9] 吴清芳,吕德良,管红云,等. 2007-2016年深圳市肺结核病流行特征[J]. 热带医学杂志,2018,18(1):86-89. DOI:10.3969/j.issn.1672-3619.2018.01.023.
[10] 沈鸿程,杜雨华,吴桂锋,等. 2008-2018年广州市报告新发肺结核流行特征分析[J]. 中国防痨杂志,2020,42(4):322-326. DOI:10.3969/j.issn.1000-6621.2020.04.005.
[11] 蔡晓婷,杜雨华,钟静,等. 2014-2018年广州市海珠区登记结核病患者流行病学特征分析[J]. 结核病与肺部健康杂志,2019,8(2):100-105. DOI:10.3969/j.issn.2095-3755. 2019.02.006.
[12] 赖静文,郭婉如,刘英,等. 2015-2020年广州市番禺区肺结核患者流行病学特征[J]. 江苏预防医学,2022,33(5):554-555,571. DOI:10.13668/j.issn.1006-9070.2022. 05.017.
[13] Uplekar M, Raviglione M. WHO's end TB strategy: from stopping to ending the global TB epidemic [J]. Indian J Tuberc, 2015, 62(4):196-199. DOI: 10.1016/j.ijtb. 2015.11.001.
[14] Fukunaga R, Glaziou P, Harris JB, et al. Epidemiology of tuberculosis and progress toward meeting global targets - worldwide, 2019 [J]. MMWR Morb Mortal Wkly Rep, 2021, 70(12):427-430. DOI: 10.15585/mmwr.mm7012a4.
[15] Reid M, Yamey G, Goosby E, et al. Seizing opportunities to end TB: a call for ambition and optimism on World TB Day [J]. Lancet, 2023, 401(10383):1153. DOI: 10.1016/S0140-6736(23)00622-0.
[16] Kasaeva T, Dias HM, Pai M. Fast-tracking progress to End TB: high-level opportunities for investment and action [J]. Lancet, 2023, 401(10381):975-978. DOI: 10.1016/S0140-6736(23)00460-9.
[17] Langer AJ, Navin TR, Winston CA, et al. Epidemiology of tuberculosis in the United States [J]. Clin Chest Med, 2019, 40(4): 693-702. DOI: 10.1016/j.ccm.2019.07.001.
[18] Cui Y, Shen H, Wang F, et al. A long-term trend study of tuberculosis incidence in China, India and United States 1992-2017: a joinpoint and age-period-cohort analysis [J]. Int J Environ Res Public Health, 2020, 17(9): 3334. DOI: 10.3390/ijerph17093334.
[19] Schildknecht KR, Pratt RH, Feng PI, et al. Tuberculosis - United States, 2022 [J]. MMWR Morb Mortal Wkly Rep, 2023, 72(12):297-303. DOI: 10.15585/mmwr.mm7212a1.
[20] Kirby T. Global tuberculosis progress reversed by COVID-19 pandemic [J]. Lancet Respir Med, 2021, 9(12): e118-e119. DOI: 10.1016/S2213-2600(21)00496-3.
[21] Reuter A, Hughes J, Furin J. Challenges and controversies in childhood tuberculosis [J]. Lancet, 2019, 394(10202): 967-978. DOI: 10.1016/S0140-6736(19)32045-8.
|